obstructive cholestasis
Conditions
Interventions
Rifampicin 150 mg twice a day for seven days and blood samples (3x 15 ml)
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Male or female with severe obstructive cholestasis for whom biliary drainage by PTC or nasobiliary drainage by ERCP is clinically indicated. - An established diagnosis of obstructive cholestasis by ultrasound-scan (US-scan), magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic retrograde cholangiopancreatography (ERCP). - Age 18-90 years - Able to understand and give fully informed written consent - Hyperbilirubinemia > 170 umol/L - Cholestatic serum enzyme pattern
Exclusion criteria
Exclusion criteria: - Patients with purely hepatocellular, non-obstructive cholestasis in whom biliary drainage by PTC or ERCP is not clinically indicated - Patients with known allergy to rifampicin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum bilirubin levels | — |
Secondary
| Measure | Time frame |
|---|---|
| • Quality of life (QoL; SF-36) and itch intensity (VAS), • Serum: bilesalt profil, lysofosfaticid acid, autotaxine, fribroblast growth factor 19, Asat, Alat, alkaline phosphatase and gamma-glutamyltransferase • Bile: lysofosfaticid acid, autotaxine, fribroblast growth factor 19 and bicarbonate | — |
Countries
Netherlands
Outcome results
None listed